Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1

Conditions

Peritoneal Neoplasms 2Hyperthermia 2Carcinoma 2Pleural Effusion, Malignant 1Myeloproliferative Disorder, Chronic, with Eosinophilia 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Appendiceal Neoplasms 1Adrenocortical Carcinoma 1Abdominal Neoplasms 1

Interventions

Cisplatin 12Pemetrexed 6Radiotherapy 5Platinum 4Doxorubicin 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Mitomycin 3Gemcitabine 3Decitabine 3pembrolizumab 2Vinorelbine 2SS1(dsFv)PE38 2Interferon-gamma 2Gene Expression Profiling 2Erlotinib Hydrochloride 2Depsipeptides 2Cyclophosphamide 2Celecoxib 2sargramostim 1rilotumumab 1ranpirnase 1methoxyamine 1entinostat 1decitabine and cedazuridine drug combination 1cixutumumab 1belinostat 1atezolizumab 1anetumab ravtansine 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma, Malignant × Cytoreduction Surgical Procedures × Clear all
NCT05375825 2024-02-02

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
MyeloidOther solid neoplasmThoracic

Myeloproliferative Disorder, Chronic, with Eosinophilia, Mesothelioma, Malignant, Carcinoma, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡